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The EBV DNA polymerase accessory protein, BMRF1, is an essential component of the viral DNA polymerase and is
required for lytic EBV replication. In addition to its polymerase accessory protein function, we have recently reported that
BMRF1 is a transcriptional activator, inducing expression of the essential oriLyt promoter, BHLF1. Here we have precisely
mapped the BMRF1-response element in the BHLF1 promoter. We demonstrate that a region of oriLyt (the ‘‘downstream
component’’), previously shown to be one of two domains absolutely essential for oriLyt replication, is required for BMRF1-
induced activation of the BHLF1 promoter. Furthermore, the downstream component of oriLyt is sufficient to confer BMRF1-
responsiveness to a heterologous promoter. The downstream component contains Sp1 binding sites, and confers Sp1-
responsiveness to a heterologous promoter. A series of plasmids containing various portions of the oriLyt downstream
component were constructed and analyzed for their ability to respond to the BMRF1 versus Sp1 transactivators. Although
the BMRF1-responsive region of the downstream component overlaps the Sp1-responsive element, certain oriLyt sequences
required for maximal BMRF1-responsiveness were not required for maximal Sp1-responsiveness. In particular, a site-
directed mutation altering the downstream component sequence GATGG (located from 0588 to 0592 relative to the BHLF1
transcription initiation site) did not affect Sp1-responsiveness, but reduced BMRF1-responsiveness by 75% and abolished
oriLyt replication. Although BMRF1 possesses nonspecific DNA binding activity, we were unable to demonstrate specific
BMRF1 binding to the downstream component of oriLyt. Our results suggest that BMRF1-induced activation of the essential
downstream component of oriLyt may play an important role in oriLyt replication. q 1997 Academic Press
INTRODUCTION encoded polymerase and uses a separate origin of repli-
cation, oriLyt (Gruffat et al., 1995; Hammerschmidt and
Epstein–Barr virus (EBV), a human gammaherpesvi-
Sugden, 1988; Schepers et al., 1993a and b). Lytic EBV
rus, causes infectious mononucleosis and is closely as-
infection can be induced by expression of the BZLF1
sociated with several types of human malignancy, includ-
immediate-early protein in B cells (Chevallier-Greco eting B-cell lymphomas and nasopharyngeal carcinoma
al., 1986; Countryman and Miller, 1985; Kenney et al.,(Miller 1990; Zur Hausen et al., 1970). EB virus infects
1989; Rooney et al., 1988; Takada and Ono, 1986), orand immortalizes human primary B lymphocytes in vitro
expression of either BZLF1 or the BRLF1 immediate-early(Miller, 1990). In B cells, the virus is generally maintained
viral protein in epithelial cells (Zalani et al., 1996). BZLF1in a latent state, and replicated as an episome using oriP
and BRLF1 transcriptionally activate the early viral pro-and the cellular DNA replication machinery (Kieff and
teins required for replication of oriLyt (Buisson et al.,Leibowitz, 1990; Miller, 1990; Reissman et al., 1985; Yates
1989; Chevallier-Greco et al., 1989; Cox et al., 1990; Far-et al., 1985). Chemical reagents, including TPA and so-
rell et al., 1989; Fixman et al., 1992, 1995; Hardwick etdium butyrate, or cross-linking of surface immunoglobu-
al., 1988, 1992; Holley-Guthrie et al., 1990; Lieberman etlin, can induce lytic viral replication in at least a portion
al., 1989; Quinlivan et al., 1993).of EBV-infected B cells (Luka et al., 1979; Takada and
Although most strains of EBV contain two copies ofOno, 1989; Zur Hausen et al., 1979). In contrast to B cells,
oriLyt, one copy (as found in the prototype B95-8 strain)EBV infection of epithelial cells commonly results in lytic
is sufficient for replication (Hammerschmidt and Sugden,infection (Li et al., 1992; Miller, 1990; Sixby et al., 1984).
1988). OriLyt overlaps the divergent promoters of theDuring lytic infection, the virus is replicated by a virally
BHRF1 and BHLF1 genes. The BHRF1 gene encodes a
bcl-2 homolog which inhibits apoptosis (Henderson et
1 To whom correspondence and reprint requests should be ad- al., 1993). The BHLF1 gene is the most actively tran-
dressed at Departments of Medicine and Microbiology and Immunol- scribed gene during lytic EBV infection, although the pre-ogy, CB#7295, Rm 211, Lineberger Comprehensive Cancer Center, Uni-
cise function of the BHLF1 gene product remains un-versity of North Carolina at Chapel Hill, Chapel Hill, North Carolina,
27599-7295. Fax: (919) 966-3015. E-mail shann@med.unc.edu. known (Laux et al., 1985; Lieberman et al., 1989).
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Hammerschmidt et al. have published extensive muta- ologous promoter. Although the downstream component
also confers Sp1-responsiveness, a mutation which sig-tional analyses of oriLyt, showing that only two regions
of oriLyt, the ‘‘upstream component’’ and the ‘‘downstream nificantly reduces BMRF1-responsiveness, without af-
fecting Sp1-responsiveness, has been identified. Thiscomponent,’’ are absolutely essential for replication
(Gruffat et al., 1995; Schepers et al., 1993). The upstream mutation (located between 0588 and 0592 relative to
the BHLF1 initiation site) also abolishes oriLyt replica-component overlaps the BHLF1 proximal promoter and
contains two BZLF1 binding sites, the BHLF1 TATA box tion. Our results suggest that BMRF1-induced transcrip-
tional activation of the downstream component of oriLytand a CCAAT box motif (Schepers et al., 1993). The down-
stream component is located from 0554 to 0632 relative may be required for lytic EBV replication.
to the BHLF1 mRNA start site and contains Sp1 binding
motifs (Gruffat et al., 1995). However, detailed mutational MATERIALS AND METHODS
analysis of the downstream component has shown that
Cell linessequences required for oriLyt replication do not correlate
precisely with the Sp1 binding sites and cannot be func- HeLa is a cervical epithelial cell line. The D98/HE-R-
tionally replaced with the canonical Sp1 sites from the 1 cell line was formed by fusion of a HeLa subclone
SV40 promoter (Gruffat et al., 1995). Therefore, it has (D98) with the EBV-positive Burkitt’s lymphoma, P3HR-1
been suggested that a cellular protein other than Sp1 (Glaser and O’Neill, 1972). HeLa and D98/HE-R-1 cells
(as yet undefined) may bind directly to the downstream were grown in Dulbecco modified Eagle medium H with
component and be essential for oriLyt replication (Gruffat 10% fetal calf serum. DG75, an EBV-negative Burkitt’s
et al., 1995). lymphoma B-cell line, was maintained in RPMI 1640 me-
OriLyt replication requires the gene products of six dium with 10% fetal calf serum. Schneider line 2 (SL2) is
viral genes: BALF5 (the catalytic component of the viral a Drosophila embryo cell line (Schneider, 1972) and was
DNA polymerase), BMRF1 (the polymerase accessory grown in Drosophila Schneider media obtained from
protein), BALF2 (single-stranded DNA-binding protein), GIBCO-BRL with 10% fetal calf serum.
BSLF1 (primase), BBLF4 (helicase), and BBLF2/3 (heli-
case-primase-associated protein) (Fixman et al., 1992, Plasmids
1995). In addition, the immediate-early gene product,
BZLF1, plays an essential role in lytic EBV replication. The oriLytDKpn plasmid (used in plasmid replication
assays) was made by ligating the EBV SstII– HincII frag-BZLF1 binds directly to oriLyt and is also required for
activation of the viral replicative genes (Guo and DePam- ment (EBV sequences 52,623 to 53,819) (Baer et al., 1984)
into the HincII site of the pBS-CAT plasmid (a gift fromphilis, 1992; Schepers et al., 1993; Takada and Ono,
1989). Frank Funari). The control oriLyt plasmid contains the
same SstII–HincII fragment inserted into the pBS vectorThe BMRF1 gene product is a dsDNA binding protein
which is essential for processive DNA synthesis by the (Stratagene). The nonessential KpnI–KpnI fragment of
oriLyt (EBV sequences 52,944 to 53,207) was subse-BALF5 gene product and is the major early phosphopro-
tein induced during EBV lytic replication (Chen et al., quently deleted from both oriLyt plasmids. The BHLF1-
CAT plasmid contains the NsiI–SacII DNA fragment of1995; Chiou et al., 1985; Cho et al., 1985; Kallin et al.,
1985; Kiehl and Dorsky, 1991, 1995; Li et al., 1987; Pear- EBV (sequences 52,623 to 53,581; 0789 to /165 relative
to the RNA start site of the BHLF1 promoter) linked toson et al., 1983; Tsurumi, 1993a and b). We have recently
reported that in addition to its role as the DNA polymer- the chloramphenicol acetyltransferase (CAT) gene in the
pBS vector (Stratagene). The KpnI–KpnI fragment fromase accessory protein, BMRF1 transactivates the early
BHLF1 promoter, while not affecting the BHRF1 promoter 52,944 to 53,207 has been deleted from BHLF1-CAT. A
series of deletions in the BHLF1-CAT plasmid were con-(Zhang et al., 1996). Although the BMRF1 gene product
alone induces significant BHLF1 activation, the com- structed by cutting at convenient restriction enzyme sites
and religating (Fig. 3A). These constructs are named tobination of the BZLF1 and BMRF1 gene products is re-
quired for maximal activation (Zhang et al., 1996). Given reflect the nucleotides present in each plasmid (relative
to the BHLF1 initiation site). A series of additional BHLF1the overlap between the BHLF1 promoter elements and
the essential domains of oriLyt, control of BHLF1 tran- promoter constructs were made using the polymerase
chain reaction (PCR) method to clone portions of thescription could potentially play a pivotal role in oriLyt
replication. BHLF1 promoter into the pBS-CAT vector as shown in
Fig. 3B. This series of constructs, which each containIn this study, we have mapped the domain in the
BHLF1 promoter required for BMRF1-responsiveness. the same 3* end and progressively longer 5* ends, is
named to reflect the BHLF1 promoter sequences presentWe demonstrate that BMRF1-induced activation of
BHLF1 is mediated through the essential downstream in each construct. A series of BHLF1 promoter fragments
amplified by PCR were also cloned into the PstI andcomponent of oriLyt. The downstream component is suffi-
cient for transferring BMRF1- responsiveness to a heter- XbaI sites upstream of the E1b promoter in the E1b-CAT
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construct (a gift from Michael Green) as shown in Fig. 4. merschmidt and Sugden, 1988). The wild-type or mutant
oriLytDKpn plasmids (containing the wild-type or mu-The E1b-CAT construct contains the minimal adenovirus
E1b promoter linked to the CAT gene (Lillie and Green, tated oriLyt sequence in pBS-CAT) were transfected into
D98/HE-R-1 cells with either pHD1013 vector DNA or the1989). Site-directed mutants of BHLF1 and oriLyt con-
structs were made using a Bio-Rad Muta Gene phagemid BZLF1 expression plasmid and a control oriLyt plasmid
(containing the minimal oriLyt in pBS). Total cellular DNAin vitro mutagenesis kit as described by the manufac-
turer. The BHRF1-CAT construct contains the early EBV was harvested 3 days after transfection, cut with the
BamHI and DpnI restriction enzymes, separated on anBHRF1 promoter sequences (from 0972 to /46 relative
to the RNA start site) linked to the CAT gene in the pBS- agarose gel, and analyzed by the Southern blot technique
using a 32P-labeled single-stranded RNA probe spanningCAT vector. The BMRF1 expression plasmid has been
previously described (Zhang et al., 1996) and contains oriLyt. The efficiency of replication was determined by
quantitating the amount of the replicated (Dpn-resistant)the 1341 base pair BclI– BglII fragment of the EBV BamHI
M fragment subcloned in the BamHI and BglII sites of band in each condition, with the control oriLyt plasmid
serving as a control for transfection and replication effi-the pSG5 vector (Stratagene), under the control of the
simian virus 40 (SV40) early promoter. The BMRF1 in ciency.
vitro translation plasmid contains the identical BclI–BglII
fragment inserted into the pBS vector (Stratagene). The Electromobility shift assays
construction of the glutathione S-transferase (GST)–
BMRF1 fusion protein has been previously described Electromobility shift assays (EMSA) were performed
as previously described (Garner and Revzin, 1981). DG75(Zhang et al., 1996). The GST–BMRF1 protein contains
the first 303 residues of BMRF1 cloned in-frame in the cell nuclear extracts were prepared by washing the cells
in phosphate-buffered saline, resuspending the cell pel-pGEX-3X vector, downstream of the GST protein. The
pPacSp1 plasmid contains a 2.1-kb fragment encoding let in 5 vol of CE buffer (10 mM Hepes (pH 7.6), 60 mM
KCl, 1 mM EDTA, 0.075% NP-40, 1 mM dithiothreitol, andthe C-terminal 686 amino acids of Sp1 protein driven by
the Drosophila actin promoter (Courey and Tjian, 1988). 1 mM phenylmethylsulfonyl fluoride), incubating on ice
3 min, spinning at 1200 rpm for 4 min, removing theThe pA10CAT construct contains the simian virus 40
early promoter (but not enhancer) driving the CAT gene supernatant, washing the pellet with CE buffer lacking
NP-40, and then lysing the nuclear pellet with NE buffer(Laimins et al., 1984).
(20 mM Tris (pH 8.0), 420 mM NaCl, 1.5 mM MgCl2 , 0.2
DNA transfections mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride, and
25% glycerol). Equal amounts of protein supernatantPlasmid DNA was purified using a QIAGEN Maxi kit
were incubated with 10,000 cpm of a 32P end-labeledas specified by the manufacturer. DNA was transfected
double-stranded oligonucleotide probe spanning a largeby electroporation, using 10 mg of DNA and 107 cells per
portion of the downstream component of oriLyt (5*-AAG-condition. Cells were shocked at 1500 V with a Zapper
CTTGGAACCCTATAGTGTAATCCCTCCCCCCCCTACCC-electroporation unit (Medical Electronics Shop, Univer-
CCCCCTCCCT-3*) or a mutant oligonucleotide probesity of Wisconsin). Epithelial cells were harvested and
(5*-AAGCTTGGAACCCTATAGTGTAATCCCTCCCCCC-suspended into RPMI 1640 medium prior to electropora-
CGAATTCCCCCCTCCCT-3*) which contains the sametion. Schneider line 2 (SL2) cells were transfected by the
sequence as above except for a mutation of CTACC intocalcium phosphate precipitation method as described
GAATT. Binding reactions were incubated at room tem-previously (DiNocera and Dawid, 1983). Before transfec-
perature for 15 min in a buffer consisting of 50 mM Tristion the cells were replated onto 10-mm petri dishes and
(pH 7.9), 250 mM NaCl, 2.5 mM EDTA, 5 mM dithiothreitol,allowed to grow for 20 to 24 hr.
5 mM MgCl2, and 50% glycerol. Salmon sperm DNA was
added as a nonspecific competitor DNA. After addingCAT assays
the probe, the reaction was incubated 15 min at room
Cell extracts were prepared 48 hr after transfection temperature and then incubated for an additional 45 min
and incubated at 377 with [14C] chloramphenicol in the at room temperature with 1 ml of antibody. The reaction
presence of acetyl coenzyme A as described previously was loaded onto a 4% polyacrylamide gel and run in
(Gorman et al., 1982). The percentage of acetylation of 0.51 Tris glycine buffer (0.025 M Tris and 0.19 M glycine).
chloramphenicol was quantitated by thin-layer chroma- The gel was dried and subjected to autoradiography. In
tography followed by Phosphorimager scanning (Molec- some experiments, 1.5 mg of purified bacterial Glutathi-
ular Dynamics). one S-transferase (GST) protein, or 1.5 mg of purified
GST–BMRF1 fusion protein, were added to the DG75
OriLyt plasmid replication assays
cell extracts. GST and GST–BMRF1 fusion proteins were
constructed and purified by affinity chromatography asOriLyt plasmid replication assays were performed
as previously described (Fixman et al., 1992; Ham- previously described (Zhang et al., 1996).
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BMRF1 protein used in EMSA assays was produced in transient cotransfection assays (Fig. 1). In the epithelial
HeLa cell line, the BMRF1 gene product activates theusing a pAc-BMRF1 baculovirus, containing the intact
BMRF1 open reading frame under the control of the bacu- BHLF1 promoter, but not the BHRF1 promoter, as pre-
viously described (Zhang et al., 1996) (Fig. 1A). As pre-lovirus PXIV promoter (Wang et al., 1991). Three days
after infection, Sf9 cells were washed in PBS, resus- viously reported (Oguro et al., 1987), the pA10CAT con-
struct, containing the SV40 early promoter, is also acti-pended in lysis buffer containing 50 mM Tris (pH 8.0),
40% glycerol, 1 mM EDTA, 1 mM DTT, and 1 mM PMSF, vated by the BMRF1 gene product. In contrast,
cotransfection studies done in Drosophila SL2 cellsand sonicated briefly. The supernatant was then purified
by a two-step column procedure (a P-11 phosphocellu- (which have no endogenous Sp1 activity (Courey and
Tjian, 1988)) demonstrated that Sp1 activates the BHRF1lose column, followed by a dsDNA cellulose column).
The BMRF1 peak fractions (eluted in 200–350 mM NaCl) promoter, but not the BHLF1 promoter (Fig. 1B). We have
previously shown that the pA10CAT construct, as ex-were identified by Western blot analysis and pooled.
pected, is also activated by Sp1 (Zalani et al., 1992). The
differential response of the BHRF1 and BHLF1 promotersDNase I foot printing assays
to the Sp1 versus BMRF1 transactivators indicates that
the BMRF1 effect on oriLyt transcription can be sepa-Binding reactions consisted of 50,000 cpm of 32P-end-
labeled probes spanning the oriLyt sequence and 1 ml rated from Sp1-responsiveness.
(1 footprint unit) of purified Sp1 protein (Promega) incu-
Mapping Sp1 binding sites in oriLytbated in a reaction buffer containing 50 mM Tris (pH 7.9),
250 mM NaCl, 2.5 mM EDTA, 5 mM MgCl2 , and 50% To further determine if BMRF1-induced transactivation
glycerol, incubated for 15 min at room temperature.
of the BHLF1 promoter is mediated through Sp1, we
DNase I (0.1 unit) (Promega) was added to the reaction
mapped the Sp1 binding sites in oriLyt. DNase I footprint
mixture for 60 sec, and then the reaction was terminated
analysis was performed with purified Sp1 protein (Pro-
by adding the stop buffer (100 mM NaCl, 100 mM Tris
mega), using a series of probes spanning the minimal
(pH 8.0), 0.2 mM EDTA, 1% SDS, 50 mg/ml glycogen,
oriLyt. As shown in Fig. 2, a probe spanning the BHLF1
and 50 mg/ml proteinase). The probe was precipitated
promoter sequences from 0152 to /201 (relative to the
by ethanol, dried, and equal amounts of counts were
mRNA start site) identified three Sp1 sites located down-
loaded on a 6% polyacrylamide gel containing 7 M urea
stream of the BHLF1 mRNA initiation site (/20 to /44,
and subjected to electrophoresis, followed by autoradi- /65 to /78, and /130 to /148). In addition, two large
ography.
Sp1-protected regions covering nearly all of the essential
downstream component of oriLyt (0565 to 0605 and
0608 to 0630 relative to the BHLF1 mRNA start site)RESULTS
were mapped (Fig. 2). The downstream component of
Response of the oriLyt promoters, BHLF1 and BHRF1, oriLyt, although extremely GC rich, does not contain the
to the BMRF1 and Sp1 transactivators consensus Sp1 binding motif, GGGCGG.
We recently reported that the BMRF1 gene product Mapping the BHLF1 promoter domain(s) required for
activates the BHLF1 promoter in oriLyt (Zhang et al., BMRF1 transactivation
1996). Oguro et al. previously reported that BMRF1 acti-
vates the SV40 early promoter (Oguro et al., 1987), al- To map the region(s) in the BHLF1 promoter required
for BMRF1-induced transactivation, a series of BHLF1-though two other groups did not observe BMRF1 trans-
activator function (Chen et al., 1995; Wong and Levine, CAT deletions were constructed as shown in Figs. 3A
and 3B. The various BHLF1-CAT constructs were co-1986). The SV40 early promoter contains a series of Sp1
binding sites (Briggs et al., 1986; Dynan and Tjian, 1983; transfected into HeLa cells, or DG75 cells (an EBV-nega-
tive Burkitt lymphoma line), with the SG5 control vectorKadonaga et al., 1987). The essential downstream com-
ponent of oriLyt, located several hundred basepairs up- or the BMRF1 expression vector. The parent BHLF1-CAT
construct contains the promoter sequences from 0789stream of both the BHLF1 and BHRF1 mRNA start sites,
also contains Sp1 binding sites (Gruffat et al., 1995), al- to /165 (with the internal KpnI–KpnI fragment, from
0157 to0420, deleted). Preliminary mapping results (Fig.though the functional significance of these Sp1 binding
sites for BHLF1 versus BHRF1 transcription has not been 3A) indicated that a deletion construct (0644//23) which
removes BHLF1 promoter sequences upstream of 0644reported. The presence of Sp1 binding sites in both of
the known BMRF1-responsive promoters suggests that and downstream of /23 is still efficiently activated by
BMRF1. However, a BHLF1 promoter construct con-BMRF1-induced activation may be mediated through pro-
teins which bind to the Sp1 motif, such as Sp1 or Sp3. taining sequences from 0142 to /165 is completely un-
responsive to the BMRF1 transactivator. These resultsThe effect of the BMRF1 and Sp1 transcription factors
on BHLF1 versus BHRF1 promoter activity was compared suggested that sequences between 0420 and 0644, or
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FIG. 1. Transactivation of the BHRF1 and BHLF1 promoters by BMRF1 and Sp1. (A) 5 mg of the BHLF1-CAT reporter plasmid (containing the early
EBV BHLF1 promoter), the BHRF1-CAT reporter plasmid (containing the early EBV BHRF1 promoter), or the pA10CAT plasmid (driven by the SV40
early promoter) were transfected into HeLa cells with either 5 mg of pSG5 vector DNA or 5 mg of the BMRF1 expression vector. Two days after
transfection, the percentage of acetylation of 14C-labeled chloramphenicol in each condition was measured as previously described (Gorman et al.,
1982). (B) 3 mg of the negative control plasmid, pBS-CAT (containing the CAT gene with no promoter), the BHLF1-CAT reporter plasmid, or the
BHRF1-CAT reporter plasmid were transfected into Drosophila SL2 cells with either 1 mg of the pPac-vector or 1 mg of the Sp1 expression vector.
Two days after transfection, the percentage of acetylation of 14C-labeled chloramphenicol in each condition was quantitated.
from 0142 to 0157, are required for BMRF1-respon- siveness to a heterologous promoter, a series of plas-
mids were constructed as shown in Fig. 4. In this seriessiveness.
To more precisely map the BMRF1-response element, of plasmids, BHLF1 promoter sequences (containing var-
ious portions of the essential downstream component ofa series of BHLF1 promoter plasmids were constructed
as shown in Fig. 3B. These plasmids each have the same oriLyt) were inserted upstream of the minimal adenovirus
E1b promoter in the E1b-CAT vector. The parent con-3* end (/45 relative to the BHLF1 mRNA start site) but
contain progressively shorter 5* ends. The parent con- struct, E1b-CAT (0655/0558) contains the BHLF1 pro-
moter sequences from 0588 to 0655 inserted upstreamstruct in this series, BHLF1-CAT 0655//45, is efficiently
activated by BMRF1 in either HeLa or DG75 cells. The of the E1b promoter in the same orientation as the se-
quences would normally be relative to the BHLF1 pro-promoterless vector plasmid, pBS-CAT, is not activated
by BMRF1 in either HeLa or DG75 cells (data not shown). moter. Additional plasmids were constructed which re-
move progressively larger 3* ends of the BHLF1 insert, asDeletion of the sequences between 0605 and 0655 es-
sentially abolished BMRF1-response in HeLa cells, while shown. In addition, the construct E1b-CAT (0558/0655)
contains the BHLF1 promoter sequences from 0558 tohaving a lesser effect in DG75 cells. Further removal
of the sequences between 0576 and 0605 abolished 0655 placed upstream of the E1b promoter in the oppo-
site (BHRF1) orientation. Finally, a site-directed mutationBMRF1 response in DG75 cells (Fig. 3b). A weaker
BMRF1-response element was also observed between in the E1b-CAT (0655/0558) construct, altering se-
quences between0588 and0592, was constructed. This0463 and 0518 in both cell types. However, this second
BMRF1-response element did not appear to be functional region of the BHLF1 promoter has been previously
shown by Hammerschmidt’s group to be essential forwhen sequences between 0518 and 0576 were in-
cluded in the construct, suggesting that a negatively reg- oriLyt replication (Gruffat et al., 1995; Schepers et al.,
1993).ulating element resides between 0518 and 0576.
These results suggest that in both HeLa and DG75 The ability of each of the above constructs to respond
to the Sp1 versus BMRF1 transactivators was tested incells, BHLF1 promoter sequences between 0576 and
0655 confer BMRF1-responsiveness. Interestingly, this cotransfection assays in SL2 and HeLa cells. As shown
in Fig. 4, the BHLF1 promoter sequences from 0558 toregion of the BHLF1 promoter overlaps the essential
downstream component of oriLyt and contains Sp1 bind- 0655 transferred both Sp1- and BMRF1-responsiveness
to the E1b promoter, regardless of orientation. Thus, se-ing sites (Fig. 2). To determine if the downstream compo-
nent of oriLyt is sufficient to transfer BMRF1-respon- quences outside of 0558 to 0655 are required to inhibit
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a higher level (21-fold) of Sp1-responsiveness. Thus, the
BMRF1-response element in oriLyt clearly overlaps, but
is distinct from, the Sp1-response element.
BMRF1 does not bind specifically to the downstream
component of oriLyt
BMRF1-induced transactivation of BHLF1 may be me-
diated through specific binding of BMRF1 to the down-
stream component, since BMRF1 possesses strong non-
specific DNA binding activity (Chen et al., 1995; Kiehl
and Dorsky, 1995; Tsurumi, 1993), although BMRF1 is not
known to recognize a specific DNA binding sequence. To
determine if BMRF1 can specifically bind to the down-
stream component of oriLyt, electromobility gel shift
assays were performed using BMRF1 protein derived
from a variety of sources. In vitro-translated full-length
BMRF1 protein, or a GST–BMRF1 fusion protein con-
taining the amino-terminal 303 amino acids of BMRF1,
bound to all probes tested with equal affinity, including
a probe encompassing the downstream component of
oriLyt (data not shown). DNase I footprinting experiments
performed with the GST versus GST–BMRF1 proteins
and a probe containing the essential downstream com-
ponent of oriLyt likewise did not show specific sites of
BMRF1 binding (data not shown). Partially purified, bacu-
lovirus-derived full-length BMRF1 protein (Fig. 5A) did not
bind more efficiently to a probe containing the wild-type
downstream component sequences than to a probe con-
taining a mutant downstream component sequence (al-
tered from 0588 to 0592) which has much reduced
BMRF1-responsiveness (Fig. 4B). Thus, BMRF1-induced
activation of the BHLF1 promoter was not associated
with specific BMRF1 binding to the BMRF1-response ele-
FIG. 2. Mapping Sp1 binding sites in oriLyt. A series of radioactively ment in these assays.
end-labeled probes spanning oriLyt were digested with DNase I in the
presence (/Sp1) or absence (0Sp1) of purified Sp1. A G ladder (‘‘G’’)
Binding of cellular transcription factors to the oriLytwas used to define the sequences protected for each probe. The Sp1-
protected sequences are indicated in brackets, labeled relative to the essential downstream component
position of the BHLF1 initiation site.
To examine the binding of cellular transcription factors
to the essential downstream component of oriLyt, nuclear
extracts were prepared from DG75 cells and EMSA sSp1-responsiveness in the intact BHLF1 promoter and
BMRF1-responsiveness in the intact BHRF1 promoter. were performed using wild-type and mutant (altered from
0588 to0592) probes spanning the downstream compo-Removal of the sequences from0558 to0606 reduced
BMRF1-responsiveness in HeLa cells about 7-fold. A nent. As shown in Figs. 5B and 5C, the wild-type and
mutant probes were both bound by two complexes (des-site-directed mutation between sequences 0588 and
0592 (in the context of the intact 0558 to 0655 insert) ignated ‘‘Sp3’’) which were specifically competed by cold
DNA containing the Sp1 binding motif and blocked byreduced BMRF1-responsiveness 4-fold. However, this
same mutation did not affect Sp1-responsiveness. These Sp3 antibody. These Sp3-like complexes likely represent
binding by different versions of the Sp3 protein (Kennettresults suggest that the sequences between 0588 and
0592 are required for efficient BMRF1-response, but dis- et al., submitted). The wild-type and mutant probes were
also both bound by another complex (designated ‘‘A’’),pensable for Sp1 response. In addition, the region from
0606 to 0655 (which contains one or more Sp1 binding whose identity remains unknown. Interestingly, the wild-
type, but not the mutant, probe bound to a third complexsites) is also clearly required for maximal BMRF1-respon-
siveness in HeLa cells, as shown in Fig. 3B. The se- (designated ‘‘wt’’). The ‘‘wt’’ complex was specifically com-
peted by cold competitor DNA containing the wild-typequences from 0606 to 0655 are sufficient to confer low-
level (5-fold) BMRF1-responsiveness in HeLa cells, and downstream component oriLyt sequence but not com-
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FIG. 3. Mapping the region of the BHLF1 promoter required for BMRF1-induced activation. (A) Deletion constructs of BHLF1-CAT were constructed
as shown by cutting at convenient restriction enzyme sites and religating. In the map at the top of the figure, the position of the two essential
domains of oriLyt (the upstream and downstream components) is shown, as well as the Sp1 sites (indicated by ‘‘S’’). The constructs were cotransfected
into HeLa cells with the SG5 or BMRF1 expression vectors, and the amount of CAT enzyme activity was calculated. The fold activation (and standard
deviation) induced by BMRF1 for each CAT construct (relative to the SG5 vector) is shown. (B) A series of 5* BHLF1-CAT deletion constructs were
constructed by PCR amplification, using the same 3* primer for each construct, and a series of different 5* primers. The amplified fragments were
inserted into the pBS-CAT vector upstream of the CAT gene. The various constructs were cotransfected with the SG5 and BMRF1 expression
vectors into HeLa and DG75 cells (an EBV-negative Burkitt lymphoma line). 48 hr after transfection, CAT activity was determined and the fold
activation (and standard deviation) induced by BMRF1 in each cell type is shown.
peted by competitor DNA containing the identical se- binding of particular cellular proteins to oriLyt. Interest-
ingly, in the presence of exogenously added GST –quences except for the mutation between 0588 and
0592 (data not shown). Although the exact identity of the BMRF1 protein (but not GST protein alone), Sp3 binding
(derived from DG75 cell extracts) to the downstream ori-protein(s) forming the ‘‘wt’’ complex remains unknown,
the fact that this complex binds BHLF1 promoter se- Lyt component was decreased, whereas the binding of
the ‘‘wt’’ and ‘‘A’’ complexes was not significantly affectedquences required for efficient BMRF1-responsiveness
suggests that it possibly plays a role in mediating BMRF1 (Fig. 5d). However, since a similar decrease in Sp3 bind-
ing was not observed in the lytically infected cell extracts,transactivation.
Gruffat et al. (1995) have previously reported that bind- it remains unclear whether the GST–BMRF1 effect on
Sp3 binding observed in vitro is actually relevant to theing of cellular proteins to the downstream oriLyt compo-
nent is similar using nuclear extracts derived from la- in vivo BMRF1 transactivator effect.
tently infected cells (which would lack BMRF1 protein)
and lytically EBV-infected cells (which would contain Mutation of the BHLF1 sequences from 0592 to
BMRF1 protein). We likewise observed similar levels of 0588 abolishes oriLyt plasmid replication
cellular protein binding to the downstream oriLyt compo-
nent using extracts derived from latently versus lytically The previous mapping studies clearly suggest that the
BHLF1 promoter sequences from 0588 to 0592 are im-EBV-infected cells, or DG75 cells transfected with the
pHD1013 expression vector versus the BMRF1 expres- portant for maximal BMRF1-responsiveness, with trans-
activation being reduced fourfold when these sequencession vector (data not shown). Thus, we did not find that
the presence or absence of BMRF1 in vivo alters the are altered (Fig. 4). To determine if the mutation altering
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FIG. 4. Transferring BMRF1- and Sp1-response to a heterologous promoter. Various BHLF1 promoter sequences encompassing different portions
of the essential downstream component of oriLyt were amplified by PCR as shown and inserted upstream of the adenovirus minimal E1b promoter
in the E1b-CAT vector. The 0655/0558-mut construct is identical to the 0655/0558 construct, except for a site-directed mutation altering sequences
0588 to 0592 (as shown in Fig. 6). The various constructs were cotransfected into HeLa cells with the SG5 or BMRF1 expression vectors and into
SL2 cells with the pPac- and Sp1 expression vectors. The fold-activation (relative to the control vector) induced by BMRF1 and Sp1 is shown.
the BHLF1 sequences from 0588 to 0592 also affects in each condition. Hammerschmidt’s group has observed
similar results constructing mutations which overlap theoriLyt replication, we inserted this mutation into the ori-
LytDKpn plasmid as shown in Fig. 6 and examined the 0588 to 0592 and 0570 to 0574 sequences (Gruffat et
al., 1995). These results indicate that BHLF1 promotereffect in plasmid replication assays. Two additional ori-
LytDKpn plasmid mutants were also constructed, one sequences from 0588 to 0592 are not only important for
BMRF1-induced transactivation, but are also essentialwhich alters the BHLF1 downstream Sp1 sites from /21
to /44, and another which alters the downstream com- for oriLyt replication.
ponent sequences from 0570 to 0574.
DISCUSSIONThe wild-type and mutant oriLytDKpn plasmids were
transfected into D98/HE-R-1 cells with or without a BZLF1 The EBV BMRF1 gene product is the viral DNA poly-
merase accessory protein and in this capacity plays anexpression vector and plasmid replication was quanti-
tated as previously described (Zhang et al., 1996). DNA essential role in lytic replication (Chen et al., 1995; Fix-
man et al., 1992; Kiehl and Dorsky, 1991, 1995; Li et al.,was harvested 3 days after transfection, cut with the DpnI
and Bam HI restriction enzymes, run on an agarose gel, 1987; Tsurumi, 1993). We have recently reported that the
BMRF1 gene product transcriptionally activates the oriLyttransferred to a nitrocellulose blot, and probed with a
radioactive probe specific for oriLyt sequences. The rep- promoter, BHLF1 (Zhang et al., 1996). In this report, we
have further explored the mechanism of BMRF1 trans-licated plasmid is resistant to Dpn 1 cutting. A control
construct, containing oriLyt inserted into the pBS vector, activation by precisely mapping the BMRF1-response el-
ement in oriLyt. We show that one of the two essentialwas also included in each transfection to serve as a
control for transfection and replication efficiency. domains of oriLyt, the downstream component, is re-
quired and sufficient for BMRF1 transactivation. A smallAs shown in Fig. 6, mutation of sequences from 0574
to 0570 (within the downstream component), or from mutation in the downstream component which inhibits
BMRF1-induced transactivation also abolishes oriLyt/21 to /44, did not affect oriLyt replication. However,
mutation of BHLF1 promoter sequences from 0588 to replication. Our results suggest that transcriptional acti-
vation of the downstream component of oriLyt by BMRF10592 abolished oriLyt replication in two separate experi-
ments. The replication of the control plasmid was similar may play an important role in lytic EBV replication.
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FIG. 5. Binding of BMRF1 and cellular proteins to the essential downstream component of oriLyt. (A) EMSA was performed using full-length
BMRF1 protein expressed from a baculovirus vector in Sf9 cells and partially purified as described under Materials and Methods. The BMRF1
protein was incubated with either a probe spanning the wild-type oriLyt downstream component sequence (‘‘BHLF1(0559/0603)’’ or a probe in
which the downstream component sequences (from 0582 to 0592 relative to the BHLF1 start site) had been mutated as shown in Fig. 6 (‘‘BHLF1
(0559/0603)-mut’’). Various competitor DNA’s (‘‘Comp’’) containing the Sp1 or NF-KB consensus binding motifs, or various antibodies (‘‘Ab’’), directed
against the NF-KB or BMRF1 proteins, were added to the binding reactions as indicated. Both probes bound BMRF1 with similar efficiency. The
BMRF1 complex was specifically blocked by a monoclonal antibody (‘‘E-AD,’’ Capricorn) recognizing the BMRF1 protein, but not by an antibody
directed against the NF-KB transcription factor. (B and C) DG75 cells nuclear extracts were prepared and tested for their ability to bind to the 32P-
end-labeled wild-type (WT) and mutant (MT) downstream component probes. Complexes were competed with cold competitor DNA containing the
Sp1 or Ap1 binding motifs or incubated with rabbit serum containing antibodies directed against the Sp1 protein, the Sp3 protein, or the p65 (NF-
KB) protein. The various binding complexes are indicated by arrows. The Sp3 and A complexes bind equally well to both the wild-type and mutant
probes, whereas the ‘‘wt’’ complex binds preferentially to the WT probe. Shorter (left panel) and longer (right panel) exposures of the same gel are
shown in Fig. 5B. (D) As in Figs. 5B and 5C, except that equal amounts (1.5 mg) of purified GST or BMRF1-GST proteins were added to the DG75
cell extract. The position of the GST-BMRF1 binding complex is indicated on the right of the figure.
AID VY 8470 / 6a2f$$8470 03-11-97 01:20:57 vira AP: Virology
31EBV BMRF1 PROTEIN TRANSACTIVATES oriLyt
FIG. 5—Continued
The precise mechanism by which BMRF1 transcrip- trast, deletion of the 0584 to 0606 region reduces
BMRF1 transactivation threefold. Site-directed mutationtionally activates oriLyt remains unknown. Although our
data clearly indicate that the BMRF1 versus Sp1 effects of the 0588 to 0592 sequence does not affect Sp1 re-
sponse, yet reduces BMRF1 response by more than four-on oriLyt transcription can be separated, several lines of
evidence suggest that BMRF1 may nevertheless modu- fold (Fig. 4). Finally, although the downstream component
of oriLyt is located between the divergent BHLF1 andlate Sp1 function, or the function of other closely related
members in the Sp1 transcription family. First, both the BHRF1 promoters, in the context of the intact oriLyt, only
the BHLF1 promoter responds to the BMRF1 transactiva-SV40 early promoter and the BHLF1 promoter contain
Sp1 sites, and both are responsive to the BMRF1 trans- tor, and only the BHRF1 promoter responds to the Sp1
transactivator.activator. Second, the BHLF1 promoter region from 0605
to 0655 is bound by the Sp1 transcription factor (Fig. 2) Given that our transfer experiments have not yet identi-
fied a sequence which has lost Sp1-responsiveness butand is also clearly required for BMRF1 transactivation
(Fig. 3B). Third, the BHLF1 promoter region from 0606 which remains BMRF1-responsive (Fig. 4), our data are
consistent with the hypothesis that efficient BMRF1-in-to 0655 is sufficient to confer Sp1-responsiveness to a
heterologous promoter, and likewise confers at least a duced transactivation requires both an Sp1 site and an
additional motif (possibly sequences spanning 0588 tolow level (fivefold) of BMRF1-responsiveness to a heterol-
ogous promoter (Fig. 4). Sp1 transcriptional activity is 0592 in the BHLF1 promoter). Our binding assays sug-
gest that in DG75 cells, at least, the downstream compo-regulated by several other virally encoded proteins, in-
cluding the papilloma virus E2 protein (Li et al., 1987) nent of oriLyt is primarily bound by Sp3, rather than Sp1.
Sp1 and Sp3 share extensive homology and bind to theand the HIV TAT protein (Kamine et al., 1991), and Sp1
augments replication of the SV40 and adenoviruses (Guo same DNA sequences. Sp3 can function as either a posi-
tive or negative regulator of transcription, dependingand DePamphilis, 1992; Hatfield and Hearing, 1993).
However, our data suggest that even if BMRF1 does upon the site of Sp3 translational initiation (Kennett et al.,
submitted). Purified GST–BMRF1 protein reduced Sp3act by modulating Sp1 (or Sp3) function, Sp1 sites alone
are not sufficient for BMRF1-induced transactivation. binding to the downstream oriLyt component in vitro (Fig.
5d). If Sp3 binding functions as a negative regulator ofTransfer of maximal BMRF1-responsiveness to a heterol-
ogous promoter requires additional sequences in the BHLF1 transcription in vivo, then BMRF1 could potentially
activate BHLF1 transcription by reducing Sp3 binding.downstream component of oriLyt which are not required
for Sp1 response. The BHLF1 promoter sequences from However, since we were unable to demonstrate reduced
Sp3 binding to the downstream component in lytically0584 to 0606 are not important for Sp1 response and
may in fact inhibit Sp1-induced activation (Fig. 4). In con- versus latently infected cells, the observed in vitro effect
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FIG. 6. Mutation of the BHLF1 sequence from 0588 to 0592 abolishes oriLyt replication. Three site-directed mutations in the oriLytDKpn plasmid
were constructed as shown. Mut-1 plasmid contains two mutations within Sp1 binding sites located downstream of the BHLF1 initiation site (/12
to /26 and /39 to /44). Mut-2 and Mut-3 alter sequences within the downstream component of oriLyt. Plasmids were cotransfected into D98-HE-
R-1 cells with (‘‘/Z’’) or without (‘‘0Z’’) the BZLF1 expression vector. A control oriLyt plasmid (‘‘control’’), containing wild-type oriLyt inserted into the
pBS vector, was also included in each transfection to serve as a control for transfection and replication efficiency. Three days after transfection,
the DNA was harvested, cut with the BamHI and DpnI restriction enzymes, separated on an agarose gel, transferred to a nitrocellulose blot, and
probed with a radioactive probe spanning oriLyt. The position of the Dpn1-resistant (replicated) control and test plasmids is indicated by arrows.
The wild-type ‘‘WT’’ mut-1 and mut-2 plasmids replicate with similar efficiency. The mut-3 plasmid (in which BHLF1 promoter sequences from 0588
to 0592 have been altered) had severely reduced replication capacity in two independent replication experiments.
of the GST–BMRF1 protein on Sp3 binding is not neces- tion factor might be required for BMRF1 effect. Although
we cannot completely exclude the possibility that BMRF1sarily physiologically relevant. Sp1 and Sp3 activity are
regulated by multiple other mechanisms, including phos- itself specifically binds to the downstream component,
we were unable to observe this in our electromobilityphorylation and interactions with other transcription fac-
tors (Kim et al., 1992), and BMRF1 could potentially affect shift assays. More likely, BMRF1 is indirectly tethered to
the downstream component by transcription factorsany of these other regulatory mechanisms.
which do bind directly to oriLyt, and this interaction isBMRF1-induced activation of BHLF1 could also be me-
labile under our EMSA conditions.diated through cellular transcription factors other than
Sp1 or Sp3 which bind to the GC-rich downstream com- Regardless of the precise mechanism, we did find a
significant correlation between BMRF1-responsivenessponent. Additional cellular factors (complexes ‘‘A’’ and
‘‘wt’’ in Fig. 5C) also clearly bind to this region of oriLyt and oriLyt replication. The downstream component of
oriLyt, which unquestionably plays an essential role inand their contribution, if any, to BMRF1-induced transacti-
vation remains unknown. Efficient binding by the ‘‘wt’’ oriLyt replication, is required, and sufficient, for BMRF1-
responsiveness. A site-directed mutation in the down-complex was found to require BHLF1 sequences from
0588 to 0592, which are also required for efficient stream component which inhibits BMRF1 response (al-
tering BHLF1 promoter sequences from 0588 to 0592)BMRF1-responsiveness. Thus the ‘‘wt’’ complex remains
also abolishes oriLyt replication. Therefore, BMRF1-in-an excellent candidate for mediating BMRF1-respon-
duced transcriptional activation of the oriLyt downstreamsiveness. The 0588 to 0592 motif could serve as a bind-
component may be important during lytic EBV infection.ing site for the ‘‘wt’’ cellular transcription factor, and bind-
ing by both Sp1 (and/or Sp3) and this putative transcrip- Interestingly, the two essential domains of oriLyt are
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